Biogen-backed Duchenne muscular dystrophy (DMD) treatment developer Solid Biosciences has filed to raise up to $100m.
Neurological disease therapy producer Biogen is set to exit US-based Duchenne muscular dystrophy (DMD) treatment developer Solid Biosciences, which has filed to raise up to $100m in an initial public offering.
Solid is developing therapies for DMD, a genetic muscle-wasting disease that affects one in every 3,500 to 5,000 boys, with the symptoms generally beginning to become apparent between the ages of three and five.
Although there is currently no cure for DMD, Solid’s lead product candidate, SGT-001, is…
